A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes

References

• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Committee on Quality of Health Care in America: Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: The National Academies Press, 2001
   Google Scholar
• Onglyza (saxagliptin). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company, 2011
   Google Scholar
• Galvus (vildagliptin). Full Prescribing Information. Camberley, Surrey: Novartis Pharmaceuticals UK Limited, 2012
   Google Scholar
• Januvia (sitagliptin). Full Prescribing Information. Whitehouse Station, NJ: Merck & Co. Inc., 2012
   Google Scholar
• Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-65
   PubMed Web of Science ®Google Scholar
• Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol 2010;70:807-14
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007;63:677-86
   PubMed Web of Science ®Google Scholar
• Victoza (liraglutide [rDNA origin]). Full Prescribing Information. Princeton, NJ: Novo Nordisk Inc., 2012
   Google Scholar
• Tradjenta (linagliptin). Full Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., 2012
   Google Scholar
• Byetta (exenatide). Full Prescribing Information. San Diego, CA: Amylin Pharmaceuticals Inc., 2011
   Google Scholar
• Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13:221-8
   PubMed Web of Science ®Google Scholar
• Nagajothi N, Adigopula S, Balamuthusamy S, et al. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. Am J Ther 2008;15:506-11
   PubMed Web of Science ®Google Scholar
• Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011 Mar 16;10:22 . doi: 10.1186/1475-2840-10-22
   PubMed Web of Science ®Google Scholar
• Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90-5
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503-8
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-94
   PubMed Web of Science ®Google Scholar
• White WB, Gorelick PB, Fleck P, et al. Cardiovascular events in patients receiving alogliptin: a pooled analysis of randomized clinical trials [abstract]. Diabetes 2010;59:391
   Google Scholar
• Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7 . Published online 2010 April 22. doi: 10.1186/1472-6823-10-7
   PubMed Web of Science ®Google Scholar
• Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol 2012;11:6 . Published online 2012 January 16. doi: 10.1186/1475-2840-11-6
   PubMed Web of Science ®Google Scholar
• Johansen OE, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3 . Published online 2012 January 10. doi: 10.1186/1475-2840-11-3
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2012. Diabetes Care 2012;35(Suppl 1):S11-63
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-15
   PubMed Web of Science ®Google Scholar
• Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011;54:300-7
   PubMed Web of Science ®Google Scholar
• Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-51
   PubMed Web of Science ®Google Scholar
• Sherwin RS, Anderson RM, Buse JB, et al. Prevention or delay of type 2 diabetes. Diabetes Care 2004;27(Suppl 1):S47-54
   PubMedGoogle Scholar
• , American Diabetes AssociationBantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008;31(Suppl 1):S61-78
   PubMed Web of Science ®Google Scholar
• Ceriello A. The emerging challenge in diabetes: The ‘metabolic memory'. Vascul Pharmacol 2012;57:133-8
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012;14:803-9
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008;17:753-9
   PubMed Web of Science ®Google Scholar
• The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;267:319-28
   Google Scholar
• Pories WJ, Dohm GL. Diabetes: have we got it all wrong? Hyperinsulinism as the culprit: surgery provides the evidence. Diabetes Care 2012;35:2438-22
   PubMedGoogle Scholar
• Invokana (canagliflozin). Full Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals Inc., 2013
   Google Scholar
• DeFronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011;34:789-94
   PubMed Web of Science ®Google Scholar
• Bays HE. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies. Endocr Pract 2011;17:933-8
   PubMed Web of Science ®Google Scholar
• Ranexa (ranolazine). Full Prescribing Information. Foster City, CA: Gilead Sciences Inc., 2011
   Google Scholar
• Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032-9
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157-68
   PubMed Web of Science ®Google Scholar